— Dr.
Daphne Koller
LinkedIn- www.linkedin.com/in/daphne-koller-4053a820
Founder and CEO of Insitro, USA
Dr. Koller leads Insitro, a company that integrates machine learning and high-throughput
biology to transform drug discovery and development. Her work focuses on leveraging
computational models to better understand complex diseases and identify novel therapeutic
targets.
Prior to founding Insitro, Dr. Koller co-founded Courser-a and served as a professor of
computer science at Stanford University. She has been recognised for her contributions to AI
and biomedical sciences, including being elected to the National Academy of Engineering.
— Dr. Simon Kohl
LinkedIn- www.linkedin.com/in/simon-kohl-4840a7124
Founder and CEO of Latent Labs, UK
Dr. Kohl, a former member of DeepMind’s AlphaFold team, established Latent Labs to
leverage AI in protein design, aiming to enhance and expedite drug development processes.
His work integrates computational biology and machine learning to create new proteins,
aligning with translational medicine objectives.
Having achieved so much at young age, his association with AI in biomedical is quite old and
remarkable.
Dr. Kohl has secured significant funding for Latent Labs, reflecting confidence in his approach
to revolutionising protein design using AI.
— Dr. Nicholas Tatonetti
LinkedIn - www.linkedin.com/in/nicholas-tatonetti
Vice Chair of Operations in the Department of Computational Biomedicine and Associate
Director of Computational Oncology at Cedars-Sinai Medical Centre
Dr. Tatonetti utilises data science to inform drug design and evaluate pharmaceutical
candidates for personalised medicine. His lab develops data mining approaches to
understand clinical and molecular data, combining electronic health records and genomics
databases with artificial intelligence and machine learning.Prior to joining Cedars-Sinai, Dr.
Tatonetti was an Associate Professor at Columbia University, where he served as Director of
Clinical Informatics at the Institute for Genomic Medicine and Co-Director of Bioinformatics.
— Dr. Ola Wlodek
LinkedIn - www.linkedin.com/in/olawlodek
CEO of Constructive Bio, a UK-based synthetic biology company.
She leads efforts in developing sustainable microbial factories and novel chemical building
blocks, transitioning from academic research to biotech business.
She holds a PhD in Biological Sciences from the University of Cambridge and an Executive
MBA from Warwick Business School. Dr. Wlodek’s scientific interests include genetic
engineering of GC-rich microbes, unnatural products, and peptide cyclisation. Prior to joining
Constructive Bio, she held various positions in the Cambridge biotech cluster, including Chief
Operating Officer at Reflection Therapeutics, where she oversaw external research and
development projects. Under her leadership, Constructive Bio has been recognised for its
innovative approaches. Recently, the company was awarded a grant from Innovate UK as part
of the Sustainable Medicines Manufacturing competition, aiming to transform the future of
sustainable medicine.
Her educational background includes a Master’s degree in Biotechnology from Jagiellonian
University and a PhD in Biological Sciences from the University of Cambridge.
— Dr. Ryan Copping
LinkedIn - www.linkedin.com/in/ryan-copping-roche
Vice President of Computational Catalysts within the Genentech Research and Early
Development (gRED) Computational Sciences organisation at Genentech, a member of
the Roche Group.
With a tenure at Roche spanning over two decades, Dr. Copping began his career in the UK
office and has since worked in New Jersey, New York City, and currently, the San Francisco
Bay Area.
His previous leadership positions include Global Head of Data Science Acceleration in the
Product Development Data Sciences group and Global Head of Personalised Healthcare
Analytics. In these roles, he focused on modernising tools, technologies, and methodologies
for clinical trial insights and generating novel insights from real-world data sources, such as
electronic medical records and omics datasets.
His educational background is in Statistics and Computing, and he has a strong passion for
advanced analytics, new technology, and fostering team culture and engagement. In 2022, he
was recognised as one of the top rising stars in health tech by Fierce Healthcare.
— Dr. Eric Schadt
Linkedin - www.linkedin.com/in/ericschadt
CSO at Pathos
He an American mathematician and computational biologist renowned for his work in
constructing predictive models of disease that integrate molecular biology with physiology to
enhance clinical medicine.
Bachelor’s Degree: Applied Mathematics and Computer Science from California Polytechnic
State University.
Master’s Degree: Pure Mathematics from the University of California, Davis.
Ph.D.: Biomathematics from the University of California, Los Angeles.
Senior Research Scientist at Roche Bioscience: Early in his career, Dr. Schadt worked as a
Senior Research Scientist at Roche Bioscience.
Executive Scientific Director of Genetics at Rosetta Inpharmatics: He served as the Executive
Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co.
Chief Scientific Officer at Pacific Biosciences: Prior to joining Mount Sinai in 2011, Dr. Schadt
was the Chief Scientific Officer at Pacific Biosciences.
Founding Director of the Icahn Institute for Genomics and Multi-scale Biology: At the Icahn
School of Medicine at Mount Sinai, he founded the Icahn Institute for Genomics and Multi-
scale Biology.
Chair of the Department of Genetics and Genomic Sciences: He also served as the Chair of
the Department of Genetics and Genomic Sciences at the Icahn School of Medicine.
Founder and CEO of Sema4: In 2017, Dr. Schadt founded Sema4, a patient-centered health
intelligence company dedicated to advancing healthcare through data-driven insights.
Predictive Modeling: Dr. Schadt is recognized for his expertise in constructing predictive
models of disease that link molecular biology to physiology, facilitating advancements in
clinical medicine.
Throughout his career, Dr. Schadt has received numerous accolades, such as the Thomson
Reuters World’s Most Influential Scientific Minds Award and the Merck Presidential
Fellowship Award.
Dr. Schadt’s pioneering work at the intersection of mathematics, computational biology, and
genomics has significantly advanced our understanding of complex human diseases and the
development of personalised medicine.
